Dare Bioscience, Inc. (DARE): Nasdaq/NYSE listing notice — Dare Bioscience receives Nasdaq delisting notice for bid price below $1.00 per share

Dare Bioscience, Inc.

Received Nasdaq delisting notice on Jan 17, 2024 for failing to meet minimum $1.00 bid price requirement.
Company had until Jan 16, 2024 to regain compliance but did not.
Will request a hearing before Nasdaq Hearing Panel to appeal and stay delisting.
Hearing typically scheduled 30-45 days after request; no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Dare Bioscience, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 17, 2024, the Staff notified the Company that because the Company did not timely regain compliance with the Minimum Bid Price Requirement, the Company’s common stock is subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). The Company will timely request a hearing before the Panel, which request will stay the delisting of the Company’s common stock pending the decision of the Panel following the hearing and the expiration of any extension period that may be granted by the Panel. Pursuant to published Nasdaq guidance

View on SEC.gov

Browse all listing & compliance notices →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-003071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.